4-azaleucine : An alanine derivative obtained by replacement of one of the methyl hydrogens of alanine by a dimethylamino group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 303570 |
| CHEBI ID | 88163 |
| SCHEMBL ID | 244558 |
| MeSH ID | M0040118 |
| Synonym |
|---|
| 28024-66-0 |
| nsc-192639 |
| nsc192639 |
| 4-azaleucine |
| azaleucine |
| 4746-36-5 |
| 4-aza-dl-leucine |
| 2-amino-3-(dimethylamino)propanoic acid |
| AKOS009156603 |
| KEZRWUUMKVVUPT-UHFFFAOYSA-N |
| SCHEMBL244558 |
| CHEBI:88163 |
| FT-0698447 |
| 2,2-diallylbisphenola |
| FT-0773255 |
| FT-0772560 |
| Q27160093 |
| l-ss-(n,n-dimethylamino)alanine |
| (2s)-2-amino-3-dimethylaminopropanoic acid;3-(dimethylamino)alanine;l-(c)micro-(n,n-dimethylamino) alanine |
| BCP31214 |
| 2-amino-3-(dimethylamino)propanoicacid |
| EN300-148050 |
| Class | Description |
|---|---|
| alanine derivative | An amino acid derivative resulting from reaction of alanine at the amino group or the carboxy group, or from the replacement of any hydrogen of alanine by a heteroatom. The definition normally excludes peptides containing alanine residues. |
| leucine derivative | An amino acid derivative resulting from reaction of leucine at the amino group or the carboxy group, or from the replacement of any hydrogen of leucine by a heteroatom. The definition normally excludes peptides containing leucine residues. |
| non-proteinogenic alpha-amino acid | Any alpha-amino acid which is not a member of the group of 23 proteinogenic amino acids. |
| tertiary amino compound | A compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 5 (55.56) | 18.7374 |
| 1990's | 3 (33.33) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||